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To the Editor: Regadenoson is a selective A2A adenosine receptor
agonist under investigation as a pharmacologic vasodilator in
nuclear stress myocardial perfusion imaging (MPI) (1). It has a
higher affinity for A2A receptors than adenosine and is a more
potent coronary vasodilator. It selectively dilates coronary relative
to peripheral vascular beds, potentially due to the high density of
coronary A2A receptors, and activation of a small percentage of
these receptors evokes maximal dilation (2). The use of caffeine, a
nonselective competitive A2A receptor antagonist, has been con-
traindicated before vasodilator MPI (3) because it attenuates the
coronary hyperemia caused by the nonselective adenosine receptor
agonists adenosine and dipyridamole in a dose-dependent manner
(4). The objective of this study was to determine the effects of
caffeine on regadenoson-induced hyperemic myocardial blood flow
(MBF) response.
In this phase II, double-blind, randomized, placebo-controlled
crossover study, 41 healthy volunteers (15 female) who were age 18
years or older, nonsmokers, and regular coffee drinkers received in
a blinded fashion either a 200-mg caffeine capsule—a dose
corresponding to 2 cups of coffee (5)—on Day 1 and placebo on
Day 2 or the inverse after refraining from methylxanthine-
containing products for at least 24 h.
The MBF was measured 2 h after capsule ingestion by positron
emission tomography (PET) with 15O-labeled water at rest and
immediately after intravenous administration of regadenoson
(400 g over 10 s). Quantitative values of global MBF in
milliliters per minute per gram were obtained as reported (6).
Coronary flow reserve (CFR) was calculated as the ratio of
hyperemic over resting MBF.
Continuous variables summarized as mean and SD or SE were
compared using analysis of variance. A value of p  0.05 was
considered significant.
Twenty-one volunteers in the placebo/caffeine sequence and 20
in the caffeine/placebo sequence completed the study. All subjects
(mean age  SD 27  6 years) returned for the second study day
after a washout period (2 to 14 days). Baseline caffeine levels  SE
were comparable on the 2 study days (0.36  0.09 mg/l vs. 0.23 
0.09 mg/l) and increased significantly after caffeine, but not after
placebo (4.26  0.18 mg/l vs. 0.33  0.18 mg/l).
All resting and hyperemic MBF as well as CFR values were
comparable irrespective of the sequence (caffeine/placebo or pla-
cebo/caffeine) or period (Day 1 or 2). Thus, all data were pooled
for comparison. The MBF  SE was not significantly different
between caffeine and placebo at rest (1.13  0.04 ml/min/g vs.
1.06  0.05 ml/min/g) and stress (2.98  0.14 ml/min/g vs. 3.05 
0.14 ml/min/g). Consequently, the regadenoson-induced CFR
was comparable with and without caffeine (2.75  0.16 vs. 2.97 
0.16, p  NS) (Fig. 1). The data show with 1-sided 95%
confidence that any CFR reduction associated with caffeine intake
is 20%.
Heart rate (HR)  SD during resting MBF was higher after
caffeine as compared with placebo (65  11 beats/min vs. 61  9
beats/min, p 0.05). Similarly, systolic (118 11 mmHg vs. 112
10 mm Hg, p  0.001) and diastolic (73  6 mm Hg vs. 70  7
mm Hg, p  0.001) blood pressure were higher after caffeine
versus placebo. The HR increase induced by regadenoson was
blunted by 20 beats/min (p  0.001) after caffeine, whereas blood
pressure was not significantly affected by prior caffeine ingestion.
No serious adverse event was reported. The most frequent
adverse events were dyspnea (56%), palpitations (49%), flushing
(30%), headache (28%), sensation of heaviness (28%), and pares-
thesia (19%). Caffeine pretreatment did not change the incidence
of adverse events but was associated with improved tolerability (as
assessed by a questionnaire) and attenuation of adverse event
severity.
Previous studies found a dose-dependent attenuation of
adenosine-induced and dipyridamole-induced CFR by caffeine (4).
The present study is the first to report the effect of caffeine on
coronary hyperemia induced by a selective adenosine agonist in
humans. It suggests that regadenoson-induced CFR was not
significantly affected by prior caffeine ingestion (200 mg) and
remained above 2.0 for the majority of subjects. Therefore, it seems
that caffeine blunts the vasodilatory effect of adenosine but has a
limited effect on regadenoson. This may be explained by the fact
that regadenoson has a higher A2A receptor affinity (7) and
higher receptor reserve (2) compared with adenosine, and is
administered as a bolus (as opposed to a 6-min infusion for
adenosine). Therefore, regadenoson may lead to a higher A2A
receptor occupancy and vasodilator effect compared with adenosine.
Regadenoson increases MBF by acting on coronary A2A recep-
tors, and it increases HR by acting on both chemosensory neurons
and peripheral vascular A2A receptors. There is a higher receptor
reserve for coronary A2A agonist-mediated coronary vasodilation,
and 25% occupancy by regadenoson translates into 90% maximal
vasodilation. The receptor reserve for regadenoson on peripheral
A2A receptors and chemosensory neurons, however, is unknown
and may be lower. If the effects of caffeine are inversely propor-
tional to the receptor reserve, then the higher receptor reserve
required to dilate coronary vessels than to increase HR may explain
that caffeine significantly blunted the increase in HR but had a
limited effect on MBF caused by regadenoson.
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Overall, regadenoson was well tolerated; side effects were generally
mild or moderate in severity and all self-limiting. Caffeine attenuated
the severity of side effects and improved tolerability of regadenoson.
The interaction of caffeine with adenosine-induced, dipyridamole-
induced, and even exercise-induced MBF changes (4,6) may limit the
correct detection of coronary artery disease and subsequently the proper
management of the patient, leading to the general recommendation to
withhold caffeine for 24 h before vasodilator stress testing (3). Because the
hyperemic MBF response to regadenoson after caffeine administration
lies well within the range of reported response to nonselective adenosine
receptor agonists and bicycle stress (6), the present study suggests that
regadenoson causes coronary hyperemia with and without prior caffeine
ingestion in healthy volunteers and moderate caffeine consumption may
not interfere with regadenoson stressMPI. Further study in patients with
coronary artery disease and possibly at higher caffeine doses would be
required before definitive conclusions could be drawn (8).
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Letters to the Editor
Concerns in the SESAMI Trial
In a clinical trial aiming to evaluate the safety and effectiveness
of drug-eluting stents in comparison with bare-metal stents
(BMS) in acute myocardial infarction (AMI), the description of
the end points should be clear and identical. As an important
composite clinical end point, major adverse cardiac events
(MACE) was given 3 possible full names without any definition
by Menichelli et al. (1) in the SESAMI (Sirolimus-Eluting
Stent Versus Bare-Metal Stent in Acute Myocardial Infarction)
trial, which could cause confusion. In the Methods section,
Figure 1 MBF Increased Significantly After Regadenoson
(A) Myocardial blood flow (MBF) at rest and after regadenoson; (B) regadenoson-induced coronary flow
reserve (CFR). Caffeine had no influence on resting or hyperemic MBF. Coronary flow reserve was not affected by caffeine.
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